Active	Status	Sponsor type	Region	Phase	Filter
1 Active 1 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
belizatinib (TSR-011) / GSK
NSCLC-1: Company plans to expand phase 1/2 clinical trial of the anaplastic lymphoma kinase (ALK) Inhibitor, TSR-011, to multiple clinical trial sites	Recruiting	1/2	0	RoW	TSR-011	Tesaro	ALK